RTP Mobile Logo
Cancer Conference Update, Issue 1, 2012
Released April 2012

Featuring interviews with Drs Sagar Lonial, Srdan Verstovsek, Owen A O’Connor, Brad S Kahl, Kenneth A Bauer and Hagop M Kantarjian. (Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Hematologic oncology and related blood disorders are some of the most rapidly evolving fields in all of medicine. Results presented at major conferences from a plethora of ongoing clinical trials lead to the continual emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care, the practicing hematologist-oncologist must be well informed of these advances. To bridge the gap between research and patient care, this issue of Cancer Conference Update uses one-on-one discussions with Drs Lonial, Verstovsek, O’Connor, Kahl, Bauer and Kantarjian about the integration of key data sets presented at the 2011 American Society of Hematology Annual Meeting into the practical management of patients diagnosed with a number of hematologic cancers and related blood disorders.

    LEARNING OBJECTIVES

    • Apply emerging clinical research data to the rational selection of treatment for patients with hematologic cancers.
    • Consider the potential clinical benefits and risks of maintenance therapy approaches for patients with diverse hematologic cancers.
    • Appraise emerging efficacy and safety data with novel agents and combination approaches for newly diagnosed or relapsed/refractory indolent or aggressive B- and T-cell non-Hodgkin lymphomas and multiple myeloma (MM).
    • Tailor up-front and maintenance therapy approaches for elderly patients with newly diagnosed MM (NDMM).
    • Counsel patients with JAK2 mutation-positive or mutation-negative myelofibrosis (MF) about the benefits and risks of available and emerging JAK1/JAK2 inhibitors.
    • Effectively apply the results of practice-changing clinical research to the care of patients with chronic myeloid leukemia (CML).
    • Integrate new therapeutic strategies into the best-practice management of Hodgkin lymphoma (HL).
    • Appraise recent data on the use of hypomethylating and immunomodulating agents in the treatment of acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS), and integrate this information, where appropriate, into current clinical care.
    • Counsel patients with newly diagnosed or recurrent cancer about their risk of disease- and/or treatment-related thromboembolism, and offer prophylaxis to appropriately selected patients to mitigate this safety concern.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    This CME activity contains an audio component. The participant should review the CME information and listen to the MP3s.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYDr Verstovsek had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr LonialAdvisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Merck and Company Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc. Dr O’ConnorAdvisory Committee: Allos Therapeutics, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Onyx Pharmaceuticals Inc, Spectrum Pharmaceuticals Inc; Consulting Agreements: Allos Therapeutics, Celgene Corporation, Millennium: The Takeda Oncology Company; Paid Research: Millennium: The Takeda Oncology Company. Dr KahlAdvisory Committee: Celgene Corporation, Cephalon Inc, Genentech BioOncology, GlaxoSmithKline, Millennium: The Takeda Oncology Company. Dr BauerConsulting Agreements: Bristol-Myers Squibb Company, GTC Biotherapeutics Inc, Instrumentation Laboratory, Johnson & Johnson Pharmaceuticals, LFB Biotechnologies, Pfizer Inc. Dr KantarjianPaid Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Inctye Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Celgene Corporation, Genentech BioOncology/Biogen Idec, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc and Sanofi.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: April 2012
    Expiration date: April 2013

Acknowledge and close

Listen to audio:
Cancer Conference Update, Issue 1, 2012
Released April 2012

Featuring interviews with Drs Sagar Lonial, Srdan Verstovsek, Owen A O’Connor, Brad S Kahl, Kenneth A Bauer and Hagop M Kantarjian. (Audio Content)

Read print: